Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients: the Aldo-DHF randomized controlled trial.
Katharina LechnerJohannes ScherrElke LorenzBenjamin LechnerBernhard HallerAlexander KrannichMartin HalleRolf WachterAndré DuvinageFrank EdelmannPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2021)
Higher O3I was associated with a more favorable cardiometabolic risk profile and predictive of higher submaximal/maximal aerobic capacity and lower BMI/truncal adiposity in HFpEF patients. Omega-3 fatty acid blood levels are inversely associated with cardiometabolic risk factors in HFpEF patients. Higher O3I was associated with a more favorable cardiometabolic risk profile and aerobic capacity (left) but did not correlate with echocardiographic markers for left ventricular diastolic function or neurohumoral activation (right). An O3I-driven intervention trial might be warranted to answer the question whether O3-FA in therapeutic doses (with the target O3I 8-11%) impact on echocardiographic markers for left ventricular diastolic function and neurohumoral activation in patients with HFpEF. This figure contains modified images from Servier Medical Art ( https://smart.servier.com ) licensed by a Creative Commons Attribution 3.0 Unported License.
Keyphrases
- left ventricular
- ejection fraction
- end stage renal disease
- randomized controlled trial
- risk factors
- fatty acid
- chronic kidney disease
- newly diagnosed
- heart failure
- healthcare
- peritoneal dialysis
- blood pressure
- physical activity
- hypertrophic cardiomyopathy
- body mass index
- metabolic syndrome
- patient reported
- acute coronary syndrome
- cardiac resynchronization therapy
- weight gain
- phase ii
- resistance training